Clonidine for Anxiety: Dosing Recommendations
Clonidine is not a first-line treatment for anxiety disorders and lacks FDA approval for this indication, but when used off-label, adults typically start at 0.1 mg twice daily (morning and bedtime) with gradual titration up to 0.2-0.4 mg/day in divided doses, while children with ADHD-related anxiety receive 0.1 mg at bedtime initially, not exceeding 0.4 mg/day. 1
Adult Dosing for Anxiety (Off-Label Use)
The FDA-approved dosing for clonidine's primary indication (hypertension) provides the framework for off-label anxiety use 1:
- Starting dose: 0.1 mg twice daily (morning and bedtime)
- Titration: Increase by 0.1 mg/day at weekly intervals if needed
- Typical therapeutic range: 0.2-0.6 mg/day in divided doses
- Maximum: 0.4 mg/day for anxiety (doses up to 2.4 mg/day have been studied for hypertension but rarely used)
Elderly patients should start at lower doses due to increased risk of CNS adverse effects, particularly sedation and orthostatic hypotension 2. Consider 0.1 mg once daily at bedtime initially.
Clinical Context for Adults
Research evidence shows mixed results for anxiety treatment. Short-term anxiolytic effects occur within 1 hour of administration 3, but long-term efficacy (beyond 10 weeks) is inconsistent in most patients with panic disorder 3. A small case series showed success in respiratory panic disorder subtype at 0.30-0.45 mg/day for 6 weeks 4. The 2025 review suggests clonidine may be most useful in treatment-resistant cases or when SSRIs are contraindicated 5.
Pediatric Dosing
For children, clonidine dosing differs significantly based on the indication:
ADHD (FDA-Approved in Children)
- Starting dose: 0.1 mg tablet at bedtime 6
- Titration: Increase to twice-daily dosing, then careful uptitration
- Maximum: 0.4 mg/day (doses higher than this are not recommended) 6
- Alternative: Transdermal patches available at 0.1,0.2, and 0.3 mg 6
Anxiety in Children (Off-Label)
No specific pediatric anxiety dosing guidelines exist in the evidence. The ADHD dosing framework would apply if used off-label, but clonidine is not recommended as a primary anxiety treatment in children 7. The 2020 AACAP anxiety guidelines prioritize SSRIs and CBT, with no mention of clonidine 7.
Hypertension in Children ≥12 Years
Critical Safety Considerations
Cardiovascular Monitoring
- Hypotension and bradycardia are dose-limiting, especially in elderly 2, 9
- In elderly patients receiving 300 mcg (0.3 mg), 30% required treatment for hypotension versus 0% at 150 mcg 9
- Monitor blood pressure and heart rate closely, particularly during titration
Discontinuation Protocol
Never stop clonidine abruptly - this can cause severe rebound hypertension and hypertensive crisis 2, 10. Taper gradually over 2-4 days minimum when discontinuing, especially if used >9 weeks or at higher doses 11.
Common Adverse Effects
- Sedation/somnolence (most common, dose-dependent)
- Dry mouth
- Dizziness
- Fatigue
- Orthostatic hypotension 6, 1
Drug Interactions
- Contraindicated with CYP1A2 inhibitors (e.g., oral contraceptives) when using tizanidine concurrently 11
- Caution with cardiovascular medications
- Pregnancy Category C 11
Renal Impairment Adjustments
Patients with renal impairment benefit from lower initial doses with careful monitoring 1. The elimination half-life increases from 12-16 hours to up to 41 hours in severe renal dysfunction 1. Hemodialysis removes minimal clonidine, so no supplemental dosing is needed post-dialysis 1.
Practical Prescribing Algorithm
- Confirm anxiety is treatment-resistant or SSRIs/SNRIs are contraindicated
- Screen for cardiovascular disease, especially in elderly
- Start low: 0.1 mg at bedtime (adults) or 0.1 mg at bedtime (children with ADHD)
- Monitor closely: Blood pressure and heart rate before each dose increase
- Titrate slowly: Increase by 0.1 mg weekly if tolerated and needed
- Target dose: 0.2-0.4 mg/day in divided doses for adults
- Reassess at 4-6 weeks: If no benefit, taper off gradually rather than continuing indefinitely
- Take larger portion at bedtime to minimize daytime sedation 1
Evidence Quality and Limitations
The evidence for clonidine in anxiety is very low to low quality 12. Most studies are case reports, small observational studies, or single crossover RCTs with short follow-up 12. The mechanism (reducing noradrenergic hyperactivity via alpha-2 agonism) is theoretically sound 4, 5, but clinical efficacy data are insufficient to recommend it as anything beyond a last-line option when conventional treatments fail.